Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | FGF1 | P05230 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339220 | 0.88 | NPC1 (0.64) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4110673 | 0.87 | NPC1 (0.62) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4110670 | 0.87 | CYP3A4 (0.62) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8784071 | 0.82 | CASP6 (0.60) | TRPV1KMT2AGAALMNA | |
| SCHEMBL6242889 | 0.80 | CASP6 (0.57) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5694477 | 0.79 | TRPV1 (0.77) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1339460 | 0.79 | MIF (0.55) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30184438 | 0.78 | NPC1 (1.00) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4642544 | 0.78 | NPC1 (1.00) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1337753 | 0.77 | CCR8 (0.55) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7378525-B2 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378525-B2 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378525-B2 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1590327-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040209948-A1 | CCR8 Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004058709-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | NPC1 1828/4885RAB9A 2089/4885CYP1A2 1346/4885 |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | NPC1 1855/4885RAB9A 2062/4885CYP1A2 1175/4885 |
| US-20040209948-A1 | CCR8 Inhibitors | CCR8, CCR1, CCR3 | NPC1 343/4885RAB9A 2882/4885CYP1A2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.